Literature DB >> 24302555

Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.

Megan B Salt1, Sourav Bandyopadhyay, Frank McCormick.   

Abstract

UNLABELLED: Tumors showing evidence of epithelial-to-mesenchymal transition (EMT) have been associated with metastasis, drug resistance, and poor prognosis. Heterogeneity along the EMT spectrum is observed between and within tumors. To develop effective therapeutics, a mechanistic understanding of how EMT affects the molecular requirements for proliferation is needed. We found that although cells use phosphoinositide 3-kinase (PI3K) for proliferation in both the epithelial and mesenchymal states, EMT rewires the mechanism of PI3K pathway activation. In epithelial cells, autocrine ERBB3 activation maintains PI3K signaling, whereas after EMT, downregulation of ERBB3 disrupts autocrine signaling to PI3K. Loss of ERBB3 leads to reduced serum-independent proliferation after EMT that can be rescued through reactivation of PI3K by enhanced signaling from p110α, ERBB3 reexpression, or growth factor stimulation. In vivo, we demonstrate that PIK3CA expression is upregulated in mesenchymal tumors with low levels of ERBB3. This study defines how ERBB3 downregulation after EMT affects PI3K-dependent proliferation. SIGNIFICANCE: This study describes a mechanism through which EMT transition alters the proliferative potential of cells by modulating ERBB3 expression. Furthermore, it demonstrates the potential for multiple molecular routes to drive proliferation in different cell states, illustrating how changes in EMT status can rewire signaling upstream of cell proliferation. 2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24302555     DOI: 10.1158/2159-8290.CD-13-0520

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  55 in total

1.  Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.

Authors:  Jason A Somarelli; Samantha Shetler; Mohit K Jolly; Xueyang Wang; Suzanne Bartholf Dewitt; Alexander J Hish; Shivee Gilja; William C Eward; Kathryn E Ware; Herbert Levine; Andrew J Armstrong; Mariano A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2016-09-12       Impact factor: 4.272

2.  EMT twists the road to PI3K.

Authors:  Matthew J Niederst; Cyril H Benes
Journal:  Cancer Discov       Date:  2014-02       Impact factor: 39.397

Review 3.  Drug resistance to targeted therapies: déjà vu all over again.

Authors:  Floris H Groenendijk; René Bernards
Journal:  Mol Oncol       Date:  2014-05-21       Impact factor: 6.603

4.  Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States.

Authors:  Jong Wook Kim; Omar O Abudayyeh; Huwate Yeerna; Chen-Hsiang Yeang; Michelle Stewart; Russell W Jenkins; Shunsuke Kitajima; David J Konieczkowski; Kate Medetgul-Ernar; Taylor Cavazos; Clarence Mah; Stephanie Ting; Eliezer M Van Allen; Ofir Cohen; John Mcdermott; Emily Damato; Andrew J Aguirre; Jonathan Liang; Arthur Liberzon; Gabriella Alexe; John Doench; Mahmoud Ghandi; Francisca Vazquez; Barbara A Weir; Aviad Tsherniak; Aravind Subramanian; Karina Meneses-Cime; Jason Park; Paul Clemons; Levi A Garraway; David Thomas; Jesse S Boehm; David A Barbie; William C Hahn; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2017-08-23       Impact factor: 10.304

5.  Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.

Authors:  Hidenori Kitai; Hiromichi Ebi; Shuta Tomida; Konstantinos V Floros; Hiroshi Kotani; Yuta Adachi; Satoshi Oizumi; Masaharu Nishimura; Anthony C Faber; Seiji Yano
Journal:  Cancer Discov       Date:  2016-05-06       Impact factor: 39.397

6.  Grb2-associated binder-2 gene promotes migration of non-small cell lung cancer cells via Akt signaling pathway.

Authors:  Li Jun Xu; Yu Chang Wang; Hong Wen Lan; Jun Li; Tian Xia
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

7.  Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer.

Authors:  Peter B Alexander; Rui Chen; Chang Gong; Lifeng Yuan; Jeff S Jasper; Yi Ding; Geoffrey J Markowitz; Pengyuan Yang; Xin Xu; Donald P McDonnell; Erwei Song; Xiao-Fan Wang
Journal:  J Biol Chem       Date:  2016-11-30       Impact factor: 5.157

8.  Zeb1 affects epithelial cell adhesion by diverting glycosphingolipid metabolism.

Authors:  Daniel Mathow; Federica Chessa; Mariona Rabionet; Sylvia Kaden; Richard Jennemann; Roger Sandhoff; Hermann-Josef Gröne; Alexander Feuerborn
Journal:  EMBO Rep       Date:  2015-02-02       Impact factor: 8.807

Review 9.  Molecular pathways and therapeutic targets in lung cancer.

Authors:  Emma Shtivelman; Thomas Hensing; George R Simon; Phillip A Dennis; Gregory A Otterson; Raphael Bueno; Ravi Salgia
Journal:  Oncotarget       Date:  2014-03-30

Review 10.  Update in Lung Cancer 2014.

Authors:  Avrum Spira; Balazs Halmos; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2015-08-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.